# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only compan...
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administrationFirst-in-human Phase 1 study is...
HC Wainwright & Co. analyst Yi Chen reiterates Vivani Medical (NASDAQ:VANI) with a Buy and maintains $4 price target.
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0....